AR081267A1 - Procedimiento de obtencion de la forma cristalina a del febuxostat - Google Patents
Procedimiento de obtencion de la forma cristalina a del febuxostatInfo
- Publication number
- AR081267A1 AR081267A1 ARP110101868A ARP110101868A AR081267A1 AR 081267 A1 AR081267 A1 AR 081267A1 AR P110101868 A ARP110101868 A AR P110101868A AR P110101868 A ARP110101868 A AR P110101868A AR 081267 A1 AR081267 A1 AR 081267A1
- Authority
- AR
- Argentina
- Prior art keywords
- febuxostat
- solvent
- obtaining
- acetate
- temperature
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Procedimiento de obtención de la forma cristalina A del Febuxostat por cristalización en un disolvente elegido entre acetato de etilo, acetato de isopropilo o formiato de etilo. Reivindicación 1: Procedimiento de obtención de la forma cristalina A del Febuxostat, caracterizado porque comprende las siguientes etapas: a) Disolución del Febuxostat en un disolvente elegido del grupo consistente en acetato de etilo, acetato de isopropilo y formiato de etilo en una proporción de 5 a 60 ml de disolvente por gramo de soluto, a una temperatura comprendida entre 50°C y la temperatura de ebullición de la disolución; b) Formación de cristales manteniendo la disolución resultante de la etapa a) a una temperatura comprendida entre 45°C y la temperatura de ebullición de la mezcla durante un período comprendido entre 1 y 24 horas, cuando el disolvente es acetato de etilo o acetato de isopropilo; y c) Aislamiento de la forma cristalina A del Febuxostat por enfriamiento a temperatura ambiente de: c.1.) la suspensión resultante de la etapa b), manteniéndose así durante un período comprendido entre 3 y 15 horas; o c.2.) la disolución resultante de la etapa a), sin pasar por la etapa b), manteniéndose en agitación durante un período comprendido entre 3 y 24 horas, cuando el disolvente es formiato de etilo; seguido de filtración y secado.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201031061 | 2010-07-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081267A1 true AR081267A1 (es) | 2012-07-18 |
Family
ID=44533538
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101868A AR081267A1 (es) | 2010-07-13 | 2011-05-31 | Procedimiento de obtencion de la forma cristalina a del febuxostat |
| ARP110102208A AR081659A1 (es) | 2010-07-13 | 2011-06-24 | Procedimiento de obtencion de la forma cristalina ii del febuxostat |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102208A AR081659A1 (es) | 2010-07-13 | 2011-06-24 | Procedimiento de obtencion de la forma cristalina ii del febuxostat |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130184466A1 (es) |
| EP (1) | EP2593442A1 (es) |
| JP (1) | JP2013531021A (es) |
| AR (2) | AR081267A1 (es) |
| TW (1) | TW201217346A (es) |
| UY (1) | UY33511A (es) |
| WO (1) | WO2012007487A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012038971A2 (en) | 2010-09-24 | 2012-03-29 | Hetero Research Foundation | Novel polymorphs of febuxostat |
| WO2012168948A2 (en) | 2011-06-06 | 2012-12-13 | Hetero Research Foundation | Process for febuxostat |
| CA2855923A1 (en) * | 2011-11-15 | 2013-05-30 | Mylan Laboratories Ltd | Process for the preparation of febuxostat polymorphs |
| EP2692342A1 (en) | 2012-07-30 | 2014-02-05 | Interquim, S.A. | Process for the preparation of pharmaceutical compositions comprising febuxostat in the form of tablets |
| EP3002006A1 (en) | 2014-10-01 | 2016-04-06 | Bluepharma - Industria Farmacêutica, S.A. | Pharmaceutical composition capable for the incorporation Febuxostat in the crystalline modifications F10, II, G and A |
| CN110526879B (zh) * | 2019-08-28 | 2022-06-21 | 迪嘉药业集团有限公司 | 一种小粒度非布司他的结晶制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100221041B1 (ko) * | 1990-11-30 | 1999-09-15 | 야스이 쇼사꾸 | 2-아릴티아졸 유도체 및 그의 약제학적 조성물 |
| CN101139325B (zh) | 2006-09-07 | 2010-05-12 | 上海医药工业研究院 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法 |
| CN100546985C (zh) * | 2007-06-29 | 2009-10-07 | 上海华拓医药科技发展股份有限公司 | 非布他特微晶及其组合物 |
| CN101412700B (zh) | 2007-10-19 | 2011-06-08 | 上海医药工业研究院 | 非布司他的晶型及其制备方法 |
-
2011
- 2011-05-31 AR ARP110101868A patent/AR081267A1/es not_active Application Discontinuation
- 2011-06-24 AR ARP110102208A patent/AR081659A1/es unknown
- 2011-07-11 TW TW100124419A patent/TW201217346A/zh unknown
- 2011-07-13 JP JP2013519084A patent/JP2013531021A/ja not_active Withdrawn
- 2011-07-13 EP EP11736321.8A patent/EP2593442A1/en not_active Withdrawn
- 2011-07-13 WO PCT/EP2011/061906 patent/WO2012007487A1/en active Application Filing
- 2011-07-13 US US13/809,839 patent/US20130184466A1/en not_active Abandoned
- 2011-07-13 UY UY0001033511A patent/UY33511A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201217346A (en) | 2012-05-01 |
| WO2012007487A9 (en) | 2012-06-21 |
| UY33511A (es) | 2012-01-31 |
| US20130184466A1 (en) | 2013-07-18 |
| AR081659A1 (es) | 2012-10-10 |
| EP2593442A1 (en) | 2013-05-22 |
| WO2012007487A1 (en) | 2012-01-19 |
| JP2013531021A (ja) | 2013-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081267A1 (es) | Procedimiento de obtencion de la forma cristalina a del febuxostat | |
| JP2011126894A5 (es) | ||
| JP2014518287A5 (es) | ||
| JP2012528877A5 (es) | ||
| MY191517A (en) | A clean method for preparing d, l-methionine | |
| CO6700138A1 (es) | Procedimiento de preparación de sal de l-arginina de perindoprilo | |
| NZ751256A (en) | Method for producing the crystalline form of modification a of calcobutrol | |
| RU2016142459A (ru) | Способ производства молочной кислоты | |
| SI2935255T1 (en) | PROCEDURE FOR PREPARATION OF RIVAROKSABAN | |
| JP2018502165A5 (es) | ||
| WO2015084694A3 (en) | Method for preparing crystalline insulin | |
| CN102304077A (zh) | 一种色氨酸的提纯方法 | |
| JP5827684B2 (ja) | ２−［３−シアノ−４−（２−ｉ−ブトキシ）フェニル］−４−メチル−５−チアゾール−カルボン酸（フェブキソスタット）の結晶形Ａを調製するための方法 | |
| RU2019106531A (ru) | Кристалл соли производного хиназолина | |
| RU2013122374A (ru) | Препарат, обладающий антитоксической активностью и содержащий комплексное соединение производного метилурацила с органической кислотой, и способ его получения | |
| RU2019104860A (ru) | Способ разделения солей баклофена | |
| CN105585564A (zh) | 恩曲他滨的纯化方法 | |
| AR111273A1 (es) | Proceso para la separación de isómeros ópticos de etilésteres racémicos del ácido 3-alquilpiperidin-carboxílico | |
| RU2013148308A (ru) | Способ выращивания монокристаллов натрий-висмутового молибдата | |
| JP2012193074A5 (es) | ||
| WO2015151190A1 (ja) | イルソグラジンマレイン酸塩の製造方法 | |
| WO2011058521A4 (en) | Process for the preparation of crystalline form i of l-malic acid salt of sunitinib | |
| RU2015152285A (ru) | Способ получения 6-метил-2-этилпиридин-3-ол соли (2S)-2-ацетаминопентандиовой кислоты | |
| CN106397399A (zh) | 一种泮托拉唑镁的精制方法 | |
| RU2013135510A (ru) | Способ получения карбоната натрия |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |